Sanofi and Regeneron present more positive data for Dupixent product

1:14 am Tuesday, October 11th, 2022

PARIS (Reuters) – Healthcare companies Sanofi and partner Regeneron presented on Tuesday more positive data for their Dupixent product.

The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.

(Reporting by Sudip Kar-Gupta; Editing by Christian Schmollinger)

25 minutes ago

IMF approves third review of Sri Lanka’s $2.9 billion bailout

1 hour ago

Adani CFO says US charges linked to only one business contract

6 hours ago

Investors see Treasury pick Bessent as calming US bond market worries